Ruben A. Mesa, MD

Articles

Myeloproliferative Neoplasm Management: Future Directions in Care

February 2nd 2023

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.

Sequencing and Managing Combination Therapy in Myeloproliferative Neoplasms

January 26th 2023

Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.

An Expanding Armamentarium in MPNs: Therapeutic Strategies Under Investigation

January 26th 2023

A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.

Myeloproliferative Neoplasms: Targeting CALR With Novel Therapy

January 19th 2023

Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.

What is the Role of Transplant in Managing Patients With Myelofibrosis?

January 19th 2023

Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.

Therapy in Myelofibrosis: Fedratinib and Ruxolitinib Strategies

January 12th 2023

Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.

Myelofibrosis: Nuancing the Potential of Disease Modification

January 12th 2023

A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.

Therapy in Myelofibrosis: Pacritinib

January 5th 2023

Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.

Novel Therapy in Myelofibrosis: Momelotinib

January 5th 2023

Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.

Selection and Management of JAK Inhibitor Therapy in MF

June 9th 2022

Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.

Dr. Mesa on the Future of JAK Inhibitor Therapy in Myelofibrosis

May 4th 2022

Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.

A Brief Overview of Myeloproliferative Neoplasms

April 28th 2022

Expert Stephen Oh, MD, PhD, provides a broad overview of the myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis.

Dr. Mesa on the FDA Approval of Pacritinib in Intermediate- or High-Risk Myelofibrosis With Severe Thrombocytopenia

March 1st 2022

Ruben A. Mesa, MD, discusses the accelerated FDA approval of pacritinib (Vonjo) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

Dr. Mesa on Future Research Efforts With JAK Inhibitors in Myelofibrosis

January 21st 2022

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses future research efforts with JAK inhibitors in myelofibrosis.

Dr. Mesa on Navigating the Expanding Paradigm of JAK Inhibitors in MPNs

November 19th 2021

Ruben A. Mesa, MD, discusses strategies for navigating the expanding paradigm of JAK inhibitors in myeloproliferative neoplasms.

Dr. Mesa on the Impact of Molecular Biology on Therapeutic Development in Myelofibrosis

September 11th 2021

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

Dr. Mesa on Achieving Transfusion Independence in Momelotinib-Treated Myelofibrosis

June 10th 2021

Ruben A. Mesa, MD, discusses the importance of achieving transfusion independence with momelotinib in myelofibrosis.

Dr. Mesa on the Potential Role of Momelotinib for Myelofibrosis-Associated Anemia

December 1st 2020

Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.

Dr. Mesa on Management Strategies for MPNs

October 23rd 2020

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Dr. Mesa on Remaining Challenges Faced in MPN Treatment

October 15th 2020

Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.